Substance / Medication

Irinotecan hydrochloride

SNOMED 386912006 UMLS C0594375

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Non-small cell lung cancer

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

58 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003398Phase 4Completed45 enrolled

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

NCT00006518Recruiting1029 enrolled

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676Active Not Recruiting1836 enrolled

Subcutaneous Amifostine Safety Study

NCT00158041Phase 4Completed452 enrolled

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

NCT00199017Phase 4Completed75 enrolled

View all 58 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.

Cui Jiujie, Qin Shukui, Zhou Yuhong et al. · Signal Transduct Target Ther · 2024

PMID: 39300077RCTFull text (PMC)

Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.

Kuroda Jun-ichiro, Kuratsu Jun-ichi, Yasunaga Masahiro et al. · Clin Cancer Res · 2010

PMID: 20068081Observational

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.

Takano Masashi, Kikuchi Yoshihiro, Yaegashi Nobuo et al. · Oncol Rep · 2006

PMID: 17089053Observational

Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.

Shimoyama Shouji, Aoki Fumio, Shimizu Nobuyuki et al. · Int J Clin Oncol · 2003

PMID: 12601543Observational

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.

Takatori Eriko, Shoji Tadahiro, Miura Yuki et al. · J Obstet Gynaecol Res · 2013

PMID: 23800356Case Report

Successful combination chemotherapy with irinotecan hydrochloride and cisplatin for primary gastric small cell carcinoma: report of a case.

Funahashi Hitoshi, Miyai Hirotaka, Wakasugi Takehiro et al. · World J Surg Oncol · 2013

PMID: 24099520Case ReportFull text (PMC)

[Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].

Hirakawa Hachidai, Futagami Masayuki, Yokoyama Yoshihito et al. · Gan To Kagaku Ryoho · 2011

PMID: 21566454Case Report

[Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].

Enomoto Katsuhisa, Amano Sadao, Sakurai Kenichi et al. · Gan To Kagaku Ryoho · 2005

PMID: 16315940Case Report

Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.

Nishida Masato, Tsunoda Hajime, Ichikawa Yoshihito et al. · Int J Clin Oncol · 2004

PMID: 15549593Case Report

[Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].

Shimoyama Shouji, Imamura Kazuhiro, Katayama Atomu et al. · Gan To Kagaku Ryoho · 2004

PMID: 15222115Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Irinotecan hydrochloride (substance)
SNOMED CT: 386912006
UMLS CUI: C0594375

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.